DuraSite

DuraSite®

Ophthalmology A sustained-release system designed to permit the gradual release of a drug into the eye over a period of hrs, overcoming problems common with conventional drug delivery
References in periodicals archive ?
ISV-401 combines azithromycin with DuraSite, the company's patented drug-delivery vehicle that offers the benefits of prolonged release of an active ingredient.
ISV-205 uses the Company's proprietary DuraSite drug delivery technology, which also is incorporated into InSite Vision's ocular infection programs ISV-401 and ISV-403, and InSite Vision's retinal program ISV-616.
The DuraSite and DuraSite 2 drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing the frequency of treatment and improving the efficacy of topical drugs.
InSite Vision also is pursuing additional collaborations based on its enabling DuraSite technology platform to formulate existing ophthalmic products for sustained release in the eye and
This study enrolled more than 240 patients undergoing cataract surgery in a two-arm trial designed to evaluate the efficacy and safety of BromSite against the DuraSite vehicle alone.
Prior clinical trials of BromSite demonstrated superiority over the then market-leader, with twice the tissue penetration using a lower dose of bromfenac due to its formulation in our proprietary DuraSite vehicle.
In addition, we debuted our new DuraSite 2 ophthalmic drug delivery platform, which is designed to significantly enhance the duration of drug retention on the eye.
InSite Vision is advancing new ophthalmic products for unmet eye care needs based on its innovative DuraSite([R]) and DuraSite 2[R] platform technologies.
Patients with moderate-to-severe blepharitis (as measured using InSite Vision's proprietary BleSSSED assessment tool and standardized digital photography) were randomized into one of four study arms to receive treatment with AzaSite Plus, DexaSite, AzaSite([R]) (azithromycin 1% ophthalmic solution), or the DuraSite vehicle twice-daily for a period of 14 days.
InSite Vision Incorporated (OTCBB: INSV) today introduced DuraSite 2[R], its next-generation enhanced drug delivery system which provides a broad platform for developing superior ophthalmic therapeutics.
This study will seek to enroll approximately 240 patients undergoing cataract surgery in a two-arm trial designed to evaluate the efficacy and safety of BromSite against the DuraSite vehicle alone.
In addition, InSite has ISV-101, which combines a low dose of bromfenac with DuraSite for the treatment of dry eye disease, ready for entry into a Phase 1/2 clinical trial.